Literature DB >> 24744818

Right ventricular dysfunction in the R6/2 transgenic mouse model of Huntington's disease is unmasked by dobutamine.

Guido Buonincontri1, Nigel I Wood2, Simon G Puttick2, Alex O Ward1, T Adrian Carpenter1, Stephen J Sawiak3, A Jennifer Morton2.   

Abstract

BACKGROUND: Increasingly, evidence from studies in both animal models and patients suggests that cardiovascular dysfunction is important in HD. Previous studies measuring function of the left ventricle (LV) in the R6/2 model have found a clear cardiac abnormality, albeit with preserved LV systolic function. It was hypothesized that an impairment of RV function might play a role in this condition via mechanisms of ventricular interdependence.
OBJECTIVE: To investigate RV function in the R6/2 mouse model of Huntington's disease (HD).
METHODS: Cardiac cine-magnetic resonance imaging (MRI) was used to determine functional parameters in R6/2 mice. In a first experiment, these parameters were derived longitudinally to determine deterioration of cardiac function with disease progression. A second experiment compared the response to a stress test (using dobutamine) of wildtype and early-symptomatic R6/2 mice.
RESULTS: There was progressive deterioration of RV systolic function with age in R6/2 mice. Furthermore, beta-adrenergic stimulation with dobutamine revealed RV dysfunction in R6/2 mice before any overt symptoms of the disease were apparent.
CONCLUSIONS: This work adds to accumulating evidence of cardiovascular dysfunction in R6/2 mice, describing for the first time the involvement of the right ventricle. Cardiovascular dysfunction should be considered, both when treatment strategies are being designed, and when searching for biomarkers for HD.

Entities:  

Keywords:  Huntington’s Disease; MRI; cognitive function; heart failure; right ventricle

Mesh:

Substances:

Year:  2014        PMID: 24744818      PMCID: PMC3986496          DOI: 10.3233/JHD-130083

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  49 in total

1.  Formation of polyglutamine inclusions in non-CNS tissue.

Authors:  K Sathasivam; C Hobbs; M Turmaine; L Mangiarini; A Mahal; F Bertaux; E E Wanker; P Doherty; S W Davies; G P Bates
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

Review 2.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

3.  Conditions associated with Huntington's disease at death. A case-control study.

Authors:  D J Lanska; M J Lanska; L Lavine; B S Schoenberg
Journal:  Arch Neurol       Date:  1988-08

4.  Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.

Authors:  A Jennifer Morton; Nigel I Wood; Michael H Hastings; Carrie Hurelbrink; Roger A Barker; Elizabeth S Maywood
Journal:  J Neurosci       Date:  2005-01-05       Impact factor: 6.167

5.  Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease.

Authors:  N A Aziz; G V Anguelova; J Marinus; J G van Dijk; R A C Roos
Journal:  Eur J Neurol       Date:  2010-02-24       Impact factor: 6.089

6.  Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.

Authors:  Michael J Mihm; Deborah M Amann; Brandon L Schanbacher; Ruth A Altschuld; John Anthony Bauer; Kari R Hoyt
Journal:  Neurobiol Dis       Date:  2006-11-27       Impact factor: 5.996

7.  Dobutamine stress magnetic resonance imaging for detection of coronary artery disease.

Authors:  F P van Rugge; E E van der Wall; A de Roos; A V Bruschke
Journal:  J Am Coll Cardiol       Date:  1993-08       Impact factor: 24.094

8.  Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure.

Authors:  J Scott Pattison; Atsushi Sanbe; Alina Maloyan; Hanna Osinska; Raisa Klevitsky; Jeffrey Robbins
Journal:  Circulation       Date:  2008-05-19       Impact factor: 29.690

9.  Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo.

Authors:  Urszula Tyrankiewicz; Tomasz Skorka; Magdalena Jablonska; Pawel Petkow-Dimitrow; Stefan Chlopicki
Journal:  J Magn Reson Imaging       Date:  2012-11-02       Impact factor: 4.813

10.  A fast protocol for infarct quantification in mice.

Authors:  Guido Buonincontri; Carmen Methner; Thomas Krieg; T Adrian Carpenter; Stephen J Sawiak
Journal:  J Magn Reson Imaging       Date:  2013-01-04       Impact factor: 4.813

View more
  11 in total

1.  Long-term pulmonary and cardiovascular morbidities of neonatal hyperoxia exposure in mice.

Authors:  Renuka T Menon; Amrit Kumar Shrestha; Corey L Reynolds; Roberto Barrios; Binoy Shivanna
Journal:  Int J Biochem Cell Biol       Date:  2017-12-07       Impact factor: 5.085

2.  Progressive cardiac arrhythmias and ECG abnormalities in the Huntington's disease BACHD mouse model.

Authors:  Yujie Zhu; Isaac Shamblin; Efrain Rodriguez; Grace E Salzer; Lita Araysi; Katherine A Margolies; Ganesh V Halade; Silvio H Litovsky; Steven Pogwizd; Michelle Gray; Sabine Huke
Journal:  Hum Mol Genet       Date:  2020-02-01       Impact factor: 6.150

Review 3.  Metabolism in Huntington's disease: a major contributor to pathology.

Authors:  Akanksha Singh; Namita Agrawal
Journal:  Metab Brain Dis       Date:  2021-10-27       Impact factor: 3.655

Review 4.  Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System.

Authors:  Jonathan Janssens; Harmonie Etienne; Sherif Idriss; Abdelkrim Azmi; Bronwen Martin; Stuart Maudsley
Journal:  Front Endocrinol (Lausanne)       Date:  2014-09-01       Impact factor: 5.555

5.  Neurocardiovascular deficits in the Q175 mouse model of Huntington's disease.

Authors:  Tamara S Cutler; Saemi Park; Dawn H Loh; Maria C Jordan; Tomohiro Yokota; Kenneth P Roos; Cristina A Ghiani; Christopher S Colwell
Journal:  Physiol Rep       Date:  2017-06

Review 6.  Do Disruptions in the Circadian Timing System Contribute to Autonomic Dysfunction in Huntington's Disease?

Authors:  Saemi Park; Christopher S Colwell
Journal:  Yale J Biol Med       Date:  2019-06-27

7.  Impaired Nitric Oxide Mediated Vasodilation In The Peripheral Circulation In The R6/2 Mouse Model Of Huntington's Disease.

Authors:  Andrew D Kane; Youguo Niu; Emilio A Herrera; A Jennifer Morton; Dino A Giussani
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

8.  Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease.

Authors:  Analyne M Schroeder; Huei Bin Wang; Saemi Park; Maria C Jordan; Fuying Gao; Giovanni Coppola; Michael C Fishbein; Kenneth P Roos; Cristina A Ghiani; Christopher S Colwell
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

Review 9.  Developing stem cell therapies for juvenile and adult-onset Huntington's disease.

Authors:  Kyle D Fink; Peter Deng; Audrey Torrest; Heather Stewart; Kari Pollock; William Gruenloh; Geralyn Annett; Teresa Tempkin; Vicki Wheelock; Jan A Nolta
Journal:  Regen Med       Date:  2015       Impact factor: 3.806

10.  Altered cerebrovascular response to acute exercise in patients with Huntington's disease.

Authors:  Jessica J Steventon; Hannah Furby; James Ralph; Peter O'Callaghan; Anne E Rosser; Richard G Wise; Monica Busse; Kevin Murphy
Journal:  Brain Commun       Date:  2020-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.